Haplotype-specific suppression of experimental allergic encephalomyelitis with anti-IA antibodies.
Treatment with monoclonal antibodies directed against the IA antigens of the MHC is known to alter the course and prevent a number of experimental autoimmune diseases. To determine whether the treatment in vivo with anti-IA antibodies is haplotype-specific, we studied the development of EAE in F1 (SJL/J X BALB/c) mice following anti-IA antibody therapy. We report that treatment of animals with monoclonal antibody directed against the high responder allele product, I-As, was successful in preventing disease when therapy was begun either at the time of immunization with antigen, or following passive transfer of MBP-sensitized T cells. Therapy with antibody directed to the low responder allele product (I-Ad), while effective when used at the time of immunization with antigen, was ineffective following passive transfer of MBP-sensitized lymphocytes.
D000483:Alleles; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004198:Disease Susceptibility; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000235:genetics / Q000276:immunology*; D007116:Immunization, Passive; D007518:Isoantibodies / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C / Q000276:immunology; D008815:Mice, Inbred Strains / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation
D000911:Antibodies, Monoclonal; D000949:Histocompatibility Antigens Class II; D007518:Isoantibodies